Compare YJ & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YJ | ERNA |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.8M |
| IPO Year | 2019 | 2021 |
| Metric | YJ | ERNA |
|---|---|---|
| Price | $1.25 | $3.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 574.8K |
| Earning Date | 03-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.13 |
| 52 Week High | $2.67 | $15.88 |
| Indicator | YJ | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 34.26 |
| Support Level | $1.26 | $0.23 |
| Resistance Level | $1.62 | $7.94 |
| Average True Range (ATR) | 0.08 | 0.82 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 3.54 | 3.54 |
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.